The promise and challenge of therapeutic genome editing

References 116

1. 1.

   Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA & Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012 ).

   Not in our library10.1126/science.1225829

2. 2.

   Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA & Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013 ).

   Not in our library10.1126/science.1231143

3. 3.

   Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE & Church GM RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013 ).

   Not in our library10.1126/science.1232033

4. 4.
   RNA-programmed genome editing in human cells · 2013

   No notice
5. 5.

   Cho SW, Kim S, Kim JM & Kim J-S Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol 31, 230–232 (2013 ).

   Not in our library10.1038/nbt.2507

6. 6.

   Knott GJ & Doudna JA CRISPR-Cas guides the future of genetic engineering. Science 361, 866–869 (2018 ).

   Not in our library10.1126/science.aat5011

7. 7.

   Hidalgo-Cantabrana C, Goh YJ & Barrangou R. Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria. J. Mol. Biol 431, 21–33 (2019 ).

   Not in our library10.1016/j.jmb.2018.09.013

8. 8.

   Bao A, Burritt DJ, Chen H, Zhou X, Cao D. & Tran L-SP The CRISPR/Cas9 system and its applications in crop genome editing. Crit. Rev. Biotechnol 39, 321–336 (2019 ).

   Not in our library10.1080/07388551.2018.1554621

9. 9.

   Terns MP CRISPR-Based Technologies: Impact of RNA-Targeting Systems. Mol. Cell 72, 404–412 (2018 ).

   Not in our library10.1016/j.molcel.2018.09.018

10. 10.

    High KA & Roncarolo MG Gene Therapy. N. Engl. J. Med 381, 455–464 (2019 ).

    Not in our library10.1056/nejmra1706910

11. 11.

    Pauling L. & Itano HA Sickle cell anemia a molecular disease. Science 110, 543–548 (1949 ).

    Not in our library10.1126/science.110.2865.543

12. 12.

    Ingram VM Gene Mutations in Human Hæmoglobin: the Chemical Difference Between Normal and Sickle Cell Hæmoglobin. Nature 180, 326–328 (1957 ).

    Not in our library10.1038/180326a0

13. 13.

    Shieh PB Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy. Neurotherapeutics 15, 840–848 (2018 ).

    Not in our library10.1007/s13311-018-00687-z

14. 14.

    Min Y-L, Bassel-Duby R. & Olson EN CRISPR Correction of Duchenne Muscular Dystrophy. Annu. Rev. Med 70, 239–255 (2019 ).

    Not in our library10.1146/annurev-med-081117-010451

15. 15.

    Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R. & Olson EN Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345, 1184–1188 (2014 ).

    Not in our library10.1126/science.1254445

16. 16.

    Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, Dulay GP, Hua KL, Ankoudinova I, Cost GJ, Urnov FD, Zhang HS, Holmes MC, Zhang L, Gregory PD & Rebar EJ A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol 29, 143–148 (2011 ).

    Not in our library10.1038/nbt.1755

17. 17.

    Joglekar AV, Gray D, Kaufman ML, Urbinati F, Senadheera S, Cost G, Reik A, Holmes MC, Gregory PD, Hollis RP & Kohn DB Zinc Finger Nucleases Targeting The β-Globin Locus Drive Efficient Correction Of The Sickle Mutation In CD34+ Cells. Blood 122, 2904–2904 (2013 ).

    Not in our library

18. 18.
    Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34+ Hematopoietic Stem and Progenitor Cells · 2017

    Not checked
19. 19.

    Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M. & Veys P. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med 9, 1–9 (2017 ).

    Not in our library10.1126/scitranslmed.aaj2013

20. 20.

    Gasiunas G, Barrangou R, Horvath P. & Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl. Acad. Sci. U. S. A 109, E2579–86 (2012 ).

    Not in our library10.1073/pnas.1208507109

21. 21.

    Szostak JW, Orr-Weaver TL, Rothstein RJ & Stahl FW The double-strand-break repair model for recombination. Cell 33, 25–35 (1983 ).

    Not in our library10.1016/0092-8674(83)90331-8

22. 22.

    Stark JM, Pierce AJ, Oh J, Pastink A. & Jasin M. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol. Cell. Biol 24, 9305–9316 (2004 ).

    Not in our library10.1128/mcb.24.21.9305-9316.2004

23. 23.

    Liu J-J, Orlova N, Oakes BL, Ma E, Spinner HB, Baney KLM, Chuck J, Tan D, Knott GJ, Harrington LB, Al-Shayeb B, Wagner A, Brötzmann J, Staahl BT, Taylor KL, Desmarais J, Nogales E. & Doudna JA CasX enzymes comprise a distinct family of RNA-guided genome editors. Nature 566, 218–223 (2019 ).

    Not in our library10.1038/s41586-019-0908-x

24. 24.

    Yan WX, Chong S, Zhang H, Makarova KS, Koonin EV, Cheng DR & Scott DA Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein. Mol. Cell 70, 327–339.e5 (2018 ).

    Not in our library10.1016/j.molcel.2018.02.028

25. 25.

    Komor AC, Kim YB, Packer MS, Zuris JA & Liu DR Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016 ).

    Not in our library10.1038/nature17946

26. 26.

    Nishida K, Arazoe T, Yachie N, Banno S, Kakimoto M, Tabata M, Mochizuki M, Miyabe A, Araki M, Hara KY, Shimatani Z. & Kondo A. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 353, (2016 ).

    Not in our library10.1126/science.aaf8729

27. 27.

    Sharon E, Chen S-AA, Khosla NM, Smith JD, Pritchard JK & Fraser HB Functional Genetic Variants Revealed by Massively Parallel Precise Genome Editing. Cell 175, 544–557.e16 (2018 ).

    Not in our library10.1016/j.cell.2018.08.057

28. 28.

    Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A. & Liu DR Search-and-replace genome editing without double-strand breaks or donor DNA. Nature (2019 )

    Not in our library10.1038/s41586-019-1711-4

29. 29.

    Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP & Lim WA Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013 ).

    Not in our library10.1016/j.cell.2013.02.022

30. 30.

    Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, Qi LS, Kampmann M. & Weissman JS Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell 159, 647–661 (2014 ).

    Not in our library10.1016/j.cell.2014.09.029

31. 31.

    Pickar-Oliver A. & Gersbach CA The next generation of CRISPR-Cas technologies and applications. Nat. Rev. Mol. Cell Biol 20, 490–507 (2019 ).

    Not in our library10.1038/s41580-019-0131-5

32. 32.

    Xu X. & Qi LS A CRISPR-dCas Toolbox for Genetic Engineering and Synthetic Biology. J. Mol. Biol 431, 34–47 (2019 ).

    Not in our library10.1016/j.jmb.2018.06.037

33. 33.

    Grünewald J, Zhou R, Garcia SP, Iyer S, Lareau CA, Aryee MJ & Joung JK Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature 569, 433–437 (2019 ).

    Not in our library10.1038/s41586-019-1161-z

34. 34.

    Zhou C, Sun Y, Yan R, Liu Y, Zuo E, Gu C, Han L, Wei Y, Hu X, Zeng R, Li Y, Zhou H, Guo F. & Yang H. Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. Nature 571, 275–278 (2019 ).

    Not in our library10.1038/s41586-019-1314-0

35. 35.

    Antoniani C, Meneghini V, Lattanzi A, Felix T, Romano O, Magrin E, Weber L, Pavani G, El Hoss S, Kurita R, Nakamura Y, Cradick TJ, Lundberg AS, Porteus M, Amendola M, El Nemer W, Cavazzana M, Mavilio F. & Miccio A. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus. Blood 131, 1960–1973 (2018 ).

    Not in our library10.1182/blood-2017-10-811505

36. 36.

    Chung JE, Magis W, Vu J, Heo S-J, Wartiovaara K, Walters MC, Kurita R, Nakamura Y, Boffelli D, Martin DIK, Corn JE & DeWitt MA CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells. PLoS One 14, e0208237 (2019 ).

    Not in our library10.1371/journal.pone.0208237

37. 37.

    Bjurström CF, Mojadidi M, Phillips J, Kuo C, Lai S, Lill GR, Cooper A, Kaufman M, Urbinati F, Wang X, Hollis RP & Kohn DB Reactivating Fetal Hemoglobin Expression in Human Adult Erythroblasts Through BCL11A Knockdown Using Targeted Endonucleases. Mol. Ther. Nucleic Acids 5, e351 (2016 ).

    Not in our library10.1038/mtna.2016.52

38. 38.

    Liu N, Hargreaves VV, Zhu Q, Kurland JV, Hong J, Kim W, Sher F, MaciasTrevino C, Rogers JM, Kurita R, Nakamura Y, Yuan G-C, Bauer DE, Xu J, Bulyk ML & Orkin SH Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. Cell 173, 430–442.e17 (2018 ).

    Not in our library10.1016/j.cell.2018.03.016

39. 39.

    Shariati L, Khanahmad H, Salehi M, Hejazi Z, Rahimmanesh I, Tabatabaiefar MA & Modarressi MH Genetic disruption of the KLF1 gene to overexpress the γ-globin gene using the CRISPR/Cas9 system. J. Gene Med 18, 294–301 (2016 ).

    Not in our library10.1002/jgm.2928

40. 40.

    Martyn GE, Wienert B, Yang L, Shah M, Norton LJ, Burdach J, Kurita R, Nakamura Y, Pearson RCM, Funnell APW, Quinlan KGR & Crossley M. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nat. Genet 50, 498–503 (2018 ).

    Not in our library10.1038/s41588-018-0085-0

Cited by papers we hold 13

• Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing · 2023
  No notice
• Genotoxic effects of base and prime editing in human hematopoietic stem cells · 2023
  Corrected
• Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL · 2022
  No notice
• Nonviral Delivery of CRISPR/Cas Systems in mRNA Format · 2022
  Not checked
• Structural basis for mismatch surveillance by CRISPR–Cas9 · 2022
  Corrected
• Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins · 2022
  No notice
• Evaluation of Cells and Medium Optimization for Invitro Model of Diabetic and Electrolyte Imbalance · 2021
  Not checked
• Applications, challenges, and needs for employing synthetic biology beyond the lab · 2021
  No notice
• Viral vector‐based gene therapies in the clinic · 2021
  No notice
• Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models · 2021
  No notice
• How can nanotechnology help to combat COVID-19? Opportunities and urgent need · 2020
  No notice
• DNA Damage: From Threat to Treatment · 2020
  No notice
• Methods Favoring Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand Breaks · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.